.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,518,421

« Back to Dashboard

Claims for Patent: 8,518,421

Title:Flashmelt oral dosage formulation
Abstract: There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.
Inventor(s): Kothari; Sanjeev H. (Princeton, NJ), Desai; Divyakant S. (West Windsor, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:13/108,193
Patent Claims: 1. A flash-melt pharmaceutical dosage form comprising a medicament, two superdisintegrants, a dispersing agent and a binder wherein said medicament is aripiprazole and wherein said dispersing agent is calcium silicate and wherein said superdisintegrants are crospovidone and croscarmellose sodium, wherein based on the total weight of said dosage form, said crospovidone comprises from about 6 to about 8 percent by weight and said croscarmellose sodium comprises from about 2 to about 4 percent by weight.

2. A flash-melt pharmaceutical dosage form according to claim 1 wherein said dispersing agent comprises from about 20 to about 70 percent by weight based on the total weight of said dosage form.

3. A flash-melt pharmaceutical dosage form according to claim 1 wherein said dispersing agent comprises from about 35 to about 45 percent by weight based on the total weight of said dosage form.

4. A flash-melt pharmaceutical dosage form according to claim 1 wherein said calcium silicate is ortho-, meta- or alpha triclinic-calcium silicate.

5. A flash-melt pharmaceutical dosage form according to claim 1 wherein said calcium silicate is comprised of a combination of alpha triclinic-calcium silicate and at least one other pharmaceutical grade of calcium silicate wherein said alpha triclinic-calcium silicate comprises from about 10 percent to about 90 percent by weight of said combination.

6. A flash-melt pharmaceutical dosage form according to claim 1 wherein said medicament comprises not more than about 30 percent by weight based on the total weight of said dosage form.

7. A flash-melt pharmaceutical dosage form according to claim 1 wherein said medicament comprises not more than about 15 percent by weight based on the total weight of said dosage form.

8. A flash-melt pharmaceutical dosage form according to claim 1 wherein said superdisintegrants comprise from about 9 to about 10 percent by weight based on the total weight of said dosage form.

9. A flash-melt pharmaceutical dosage form according to claim 1 further comprising a distributing agent.

10. A flash-melt pharmaceutical dosage form according to claim 9 wherein said distributing agent comprises from about 1 to about 10 percent by weight based on the total weight of said dosage form.

11. A flash-melt pharmaceutical dosage form according to claim 10 wherein said distributing agent comprises from about 1.5 to about 3 percent by weight based on the total weight of said dosage form.

12. A flash-melt pharmaceutical dosage form according to claim 11 wherein said distributing agent is amorphous silica, fumed silica, diatomaceous earth, talc, kaolin or magnesium aluminum trisilicate.

13. A flash-melt pharmaceutical dosage form according to claim 1 wherein said binder is microcrystalline cellulose, hydroxypropyl cellulose, ethyl cellulose, lactose, mannitol or calcium phosphate.

14. A flash-melt pharmaceutical dosage form comprising a medicament, two superdisintegrants, a dispersing agent, a distributing agent and a binder wherein said medicament is aripiprazole and comprises not more than about 30 percent by weight based on the total weight of said dosage form, said dispersing agent is calcium silicate having a surface area of 1.0 m.sup.2/gm to 210 m.sup.2/gm, bulk density of 0.075 g/cc to 0.90 g/cc, true density of 1.70 g/cc to 2.90 g/cc and volatile content of less than 1 percent to 14 percent w/w and which comprises from about 35 to about 45 percent by weight based on the total weight of said dosage form, said superdisintegrants are crospovidone and croscarmellose sodium, said crospovidone comprises from about 6 to about 8 percent by weight based on the total weight of said dosage form and said croscarmellose sodium comprises from about 2 to about 4 percent by weight based on the total weight of said dosage form and wherein said distributing agent is amorphous silica, fumed silica, distomaceous earth, talc, kaolin or magnesium aluminum trisilicate and comprises from about 1 to about 10 percent by weight based on the total weight of said dosage form.

15. A flash-melt pharmaceutical dosage form comprising a medicament, two superdisintegrants, a dispersing agent, a distributing agent and a binder wherein said medicament is aripiprazole and comprises not more than about 30 percent by weight based on the total weight of said dosage form, said dispersing agent is calcium silicate having a surface area of 1.0 m.sup.2/gm to 210 m.sup.2/gm, bulk density of 0.075 g/cc to 0.90 g/cc, true density of 1.70 g/cc to 2.90 g/cc and volatile content of less than 1 percent to 14 percent w/w and which comprises from about 35 to about 45 percent by weight based on the total weight of said dosage form, said superdisintegrants are crospovidone and croscarmellose sodium, wherein said crospovidone comprises about 7 percent by weight based on the total weight of said dosage form and wherein said croscarmellose comprises about 3 percent by weight based on the total weight of said dosage form, and wherein said distributing agent is amorphous silica, fumed silica, distomaceous earth, talc, kaolin or magnesium aluminum trisilicate and comprises from about 10 to about 50 percent by weight of said binder based on the total weight of said dosage form.

16. A flash-melt pharmaceutical dosage form comprising a medicament, two superdisintegrants, a dispersing agent, a distributing agent and a binder wherein said medicament is aripiprazole and comprises not more than about 20 percent by weight based on the total weight of said dosage form, said dispersing agent is calcium silicate having a surface area of 1.0 m.sup.2/gm to 210 m.sup.2/gm, bulk density of 0.075 g/cc to 0.90 g/cc, true density of 1.70 g/cc to 2.90 g/cc, and volatile content of less than 1 percent to 14 percent w/w and which comprises from about 35 to about 45 percent by weight based on the total weight of said dosage form, said superdisintegrants are crospovidone and croscarmellose sodium, and wherein said crospovidone comprises about 7 percent by weight based on the total weight of said dosage form and wherein said croscarmellose comprises about 3 percent by weight based on the total weight of said dosage form, and wherein said distributing agent is amorphous silica, fumed silica, distomaceous earth, talc, kaolin or magnesium aluminum trisilicate and comprises from about 10 to about 50 percent by weight of said binder based on the total weight of said dosage form.

17. A flash-melt pharmaceutical dosage form comprising a medicament, two superdisintegrants, a dispersing agent, a distributing agent and a binder wherein said medicament is aripiprazole and comprises not more than about 10 percent by weight based on the total weight of said dosage form, said dispersing agent is calcium silicate having a surface area of 1.0 m.sup.2/gm to 210 m.sup.2/gm, bulk density of 0.075 g/cc to 0.90 g/cc, true density of 1.70 g/cc to 2.90 g/cc and volatile content of less than 1 percent to 14 percent w/w and which comprises from about 35 to about 45 percent by weight based on the total weight of said dosage form, said superdisintegrants are crospovidone and croscarmellose sodium and wherein said crospovidone comprises about 7 percent by weight based on the total weight of said dosage form and wherein said croscarmellose sodium comprises about 3 percent by weight based on the total weight of said dosage form.

18. A flash-melt pharmaceutical dosage form comprising a medicament, two superdisintegrants, a dispersing agent, a distributing agent and a binder wherein said medicament is aripiprazole and comprises not more than about 5 percent by weight based on the total weight of said dosage form, said dispersing agent is calcium silicate having a surface area of 1.0 m.sup.2/gm to 210 m.sup.2/gm, bulk density of 0.075 g/cc to 0.90 g/cc, true density of 1.70 g/cc to 2.90 g/cc and volatile content of less than 1 percent to 14 percent w/w and which comprises from about 35 to about 45 percent by weight based on the total weight of said dosage form, said superdisintegrants are crospovidone and croscarmellose sodium and wherein said crospovidone comprises about 7 percent by weight based on the total weight of said dosage form and wherein said croscarmellose comprises about 3 percent by weight based on the total weight of said dosage form.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc